Pfizer started to build new R&D facility in Missouri

| By | Pfizer, R&D
0
1758

Pfizer Inc., one of the world’s premier biopharmaceutical companies, broke ground on a state-of-the art Research and Development (R&D) and process development facility in Chesterfield, Missouri, USA. The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations which the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.

The facility will provide approximately 295,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. This team is responsible for advancing Pfizer’s biologics, vaccines, and gene therapy portfolio by developing manufacturing processes and dosage forms applying state-of-the-art analytical technologies, conducting non-GMP manufacturing and scale-up studies. This critical work enables the development of potential new medicines to treat ailments in oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars.

“We’ve been proud to call Missouri home since 2002,” said John Ludwig, Senior Vice President of BioTherapeutics Pharmaceutical Sciences for Pfizer. “During this time, we’ve benefitted from the excellent life sciences workforce based in Missouri, and also from a strong partnership with the State, St. Louis County, and the St. Louis Economic Development Partnership. All of these were important factors as we sought a new home where we could continue to evolve our business over the coming years.”

New state-of-the-art features of the campus will include a floor plan which provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate.

SOURCE: pfizer
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.